Literature DB >> 1549536

Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation.

V Bhatt-Mehta1, C E Johnson, R E Schumacher.   

Abstract

Extracorporeal membrane oxygenation (ECMO) may affect the pharmacokinetics of certain drugs. The objectives of this study were to determine (1) the pharmacokinetics of gentamicin in neonates on ECMO and compare them to reported values for a similar patient population not on ECMO, (2) if the pharmacokinetics of gentamicin differ between venous-venous and venous-arterial bypass, and (3) if the pharmacokinetics of gentamicin are affected by oxygenator surface area (0.6 m2 vs 0.8 m2 oxygenators). The medical records of 29 term neonates who received gentamicin while on ECMO were reviewed. Data collected included gentamicin dosage, peak and trough serum concentrations determined at steady state, duration of treatment, time on ECMO, daily weights, and pertinent laboratory values. An initial dosage of gentamicin 2.5 mg/kg every 18 hours is suggested for term neonates on ECMO. Dosage adjustments should be based on gentamicin serum concentrations, and modifications may also be required after ECMO.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1549536

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  27 in total

Review 1.  Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics.

Authors:  Matteo Di Nardo; Enno Diederick Wildschut
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 2.  Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.

Authors:  Vesa Cheng; Mohd-Hafiz Abdul-Aziz; Jason A Roberts; Kiran Shekar
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment.

Authors:  Nilesh M Mehta; David R Halwick; Brenda L Dodson; John E Thompson; John H Arnold
Journal:  Intensive Care Med       Date:  2007-04-03       Impact factor: 17.440

4.  Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation.

Authors:  R D Amaker; J T DiPiro; J Bhatia
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation.

Authors:  Kevin M Watt; Daniel K Benjamin; Ira M Cheifetz; Ganesh Moorthy; Kelly C Wade; P Brian Smith; Kim L R Brouwer; Edmund V Capparelli; Michael Cohen-Wolkowiez
Journal:  Pediatr Infect Dis J       Date:  2012-10       Impact factor: 2.129

Review 6.  Innovative clinical trial design for pediatric therapeutics.

Authors:  Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

Review 7.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

8.  The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.

Authors:  Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel
Journal:  Pediatr Clin North Am       Date:  2012-08-29       Impact factor: 3.278

Review 9.  Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates.

Authors:  Marcia L Buck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.